Kuroshima Shinichiro
Division of Oral Implantology, Graduate School of Biomedical Sciences, Nagasaki University, Oral & Maxillofacial Implant Center, Nagasaki University Hospital, Japan.
Clin Calcium. 2017;27(10):1453-1459.
Dental implant treatment is one of the most reliable therapeutic options for replacing missing teeth. In 2003, it was demonstrated that osteonecrosis of the jaw(ONJ)occurred in patients taking bisphosphonates(BRONJ). Recently, ONJ has also been demonstrated to occur in patients taking anti-receptor activator of nuclear factor-kappaB ligand antibody(denosumab:DRONJ). However, the precise mechanisms of ONJ remain unclear and definitive treatment strategies for ONJ have not been developed. There has been little information regarding the relationship between ONJ and dental implant treatment. However, a recent systematic review indicated that dental implant treatment is a triggering factor for BRONJ. The aim of this study was to provide the most current information on dental implant treatment in patients receiving anti-resorptive agents. A literature search has suggested that implant treatment becomes a risk factor for BRONJ around dental implants. Implantitis may also be a risk factor for BRONJ around dental implants. No available information regarding DRONJ around dental implants was noted. Hence, caution should be exercised when dental implant treatment is carried out in the patients taking anti-resorptive agents such as bisphosphonates and denosumab.
牙种植治疗是替代缺失牙最可靠的治疗选择之一。2003年，有研究表明服用双膦酸盐的患者会发生颌骨骨坏死（ONJ）（双膦酸盐相关颌骨骨坏死，BRONJ）。最近，也有研究表明服用抗核因子κB受体活化因子配体抗体（地诺单抗：地诺单抗相关颌骨骨坏死，DRONJ）的患者会发生ONJ。然而，ONJ的确切机制仍不清楚，且尚未制定出针对ONJ的明确治疗策略。关于ONJ与牙种植治疗之间的关系，相关信息较少。然而，最近一项系统评价表明，牙种植治疗是BRONJ的触发因素。本研究的目的是提供接受抗吸收剂治疗的患者牙种植治疗的最新信息。文献检索表明，种植治疗成为种植体周围BRONJ的一个危险因素。种植体周围炎也可能是种植体周围BRONJ的一个危险因素。未发现关于种植体周围DRONJ的可用信息。因此，在为服用双膦酸盐和地诺单抗等抗吸收剂的患者进行牙种植治疗时应谨慎。
